SynthesisJournal of the National Cancer Institute2009
Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis.
Synthesis in Journal of the National Cancer Institute, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- The microRNAs as prognostic biomarkers for survival in esophageal cancer: a meta-analysis.TheScientificWorldJournal · 2014Pooled it
- Construction and analysis of multiparameter prognostic models for melanoma outcome.Methods in molecular biology (Clifton, N.J.) · 2014Pooled it
- Systematic review and meta-analysis of tumor biomarkers in predicting prognosis in esophageal cancer.BMC cancer · 2013Pooled it
- Evaluating the quality of research into a single prognostic biomarker: a systematic review and meta-analysis of 83 studies of C-reactive protein in stable coronary artery disease.PLoS medicine · 2010Pooled it
- MKLNID: Identifying Melanoma-related Pathogenic Genes Through Multiple Kernel Learning and Network Impulsive Dynamics.Interdisciplinary sciences, computational life sciences · 2026Article
- Targeting Melanoma Cell Adhesion Molecule as a Novel Therapeutic Approach for Acral Melanoma.Experimental dermatology · 2025Article
- AnInternational journal of molecular sciences · 2025Article
- Pair-matched analysis of Circulating Melanoma Cells (CMCs) before and after Immunotherapy in Relation to other Melanoma-Specific Biomarkers.Journal of Cancer · 2025Article
- Cost-effectiveness analysis of population-basedFrontiers in public health · 2025Article
- The Prognostic Value of Proliferative Activity in Cutaneous Melanoma: A Pilot Study Evaluating the Mitotic Rate and Ki67 Index to Predict Patient Outcomes.Biomedicines · 2024Article
- The Transcriptional Landscape of Immune-Response 3'-UTR Alternative Polyadenylation in Melanoma.International journal of molecular sciences · 2024Article
- MGRN1 as a Phenotypic Determinant of Human Melanoma Cells and a Potential Biomarker.Life (Basel, Switzerland) · 2022Article
- MrgprF acts as a tumor suppressor in cutaneous melanoma by restraining PI3K/Akt signaling.Signal transduction and targeted therapy · 2022Article
- An Integrated Platform for Skin Cancer Heterogenous and Multilayered Data Management.Journal of medical systems · 2021Article
- Article
- Review of diagnostic, prognostic, and predictive biomarkers in melanoma.Clinical & experimental metastasis · 2018Review
- The fragile X mental retardation protein regulates tumor invasiveness-related pathways in melanoma cells.Cell death & disease · 2017Article
- Histamine therapeutic efficacy in metastatic melanoma: Role of histamine H4 receptor agonists and opportunity for combination with radiation.Oncotarget · 2017Article
- Article
- 5-Hydroxymethylcytosine is an independent predictor of survival in malignant melanoma.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2017Article
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
In the clinical management of early-stage cutaneous melanoma, it is critical to determine which patients are cured by surgery alone and which should be treated with adjuvant therapy. To assist in this decision, many groups have made an effort to use molecular information. However, although there are hundreds of studies that have sought to assess the potential prognostic value of molecular markers in predicting the course of cutaneous melanoma, at this time, no molecular method to improve risk stratification is part of recommended clinical practice. To help understand this disconnect, we conducted a systematic review and meta-analysis of the published literature that reported immunohistochemistry-based protein biomarkers of melanoma outcome. Three parallel search strategies were applied to the PubMed database through January 15, 2008, to identify cohort studies that reported associations between immunohistochemical expression and survival outcomes in melanoma that conformed to the REMARK criteria. Of the 102 cohort studies, we identified only 37 manuscripts, collectively describing 87 assays on 62 distinct proteins, which met all inclusion criteria. Promising markers that emerged included melanoma cell adhesion molecule (MCAM)/MUC18 (all-cause mortality [ACM] hazard ratio [HR] = 16.34; 95% confidence interval [CI] = 3.80 to 70.28), matrix metalloproteinase-2 (melanoma-specific mortality [MSM] HR = 2.6; 95% CI = 1.32 to 5.07), Ki-67 (combined ACM HR = 2.66; 95% CI = 1.41 to 5.01), proliferating cell nuclear antigen (ACM HR = 2.27; 95% CI = 1.56 to 3.31), and p16/INK4A (ACM HR = 0.29; 95% CI = 0.10 to 0.83, MSM HR = 0.4; 95% CI = 0.24 to 0.67). We further noted incomplete adherence to the REMARK guidelines: 14 of 27 cohort studies that failed to adequately report their methods and nine studies that failed to either perform multivariable analyses or report their risk estimates were published since 2005.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.